← SynDRA
MIGLITOL
SynDRA canonical compound SYN0010918 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | MGAM |
|---|
| Mechanism of action | Glucosidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- GAA
- MGAM
- AGL
- AMY2A
- GANAB
- GANC
- GBA1
- GLB1
- Gaa
- LCT
- MGA
- SI
Mechanisms of action (all sources)
- Glucosidase inhibitor
- MGAM INHIBITOR
- Maltase-glucoamylase inhibitor
- GAA INHIBITOR
- Lysosomal alpha-glucosidase inhibitor
- MGA INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- ADORA3
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SLC6A2
- SAMHD1
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- KCNH2
- HTR2B
- HTR1A
- HRH3
- HDAC6
- F2
- ESR1
- EGFR
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- AGTR1
- ADRA2A
- ADRA1A
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- alpha Glucosidase Inhibitors
- alpha-Glucosidase Inhibitor
- Enzyme Inhibitors
- Glycoside Hydrolase Inhibitors
- Hypoglycemic Agents
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- GLYSET
- diastabol
- seibule
- glyset
- BAY-M-1099
- NSC-758702
- Diastabol
- Glyset
- Plumarol
- Seibule
- Glyset (TN)
- SK-983
- Bay-m-1099
- Miglitol (JAN/USAN/INN)
- 0V5436JAQW
- NSC 758702
- BAY-m 1099
- DTXCID703323
- N-hydroxyethyl-1-desoxynojirimycin
- N-hydroxyethyl-1-desoxy-nojirimycin
- RefChem:57016
- MFCD00867240
- Miglitol (Glyset)
- Miglitolum
- N-(2-Hydroxyethyl)-1-deoxynojirimycin
- SMR000466381
- Miglitolum [Latin]
- CAS-72432-03-2
- UNII-0V5436JAQW
- Miglitol [USAN:INN:BAN]
- BAY1099;BAY-m1099
- Bay 1099
- Diastabol;
- HSDB 8022
- NCGC00095127-01
- EINECS 276-661-6
- baym1099
Reported adverse events
Look up MIGLITOL in the interactive SynDRA portal →